Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOST-Express: trastuzumab deruxtecan in HER2-positive metastatic solid tumors
2025-522058-38-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC) and 1 more (4 cohorts), sponsored by Centre Léon Bérard. Primary endpoint: Objective response rate at 18 weeks. Planned start Oct 2026; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)HER2-positive cancer (HER2+)
Beyond the preview
Go deeper on 2025-522058-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522058-38-00.